

14 November 2022

ASX Announcement

## Nasodine Composition Patent Accepted in Australia

---

- **Pharmaceutical composition patent for Nasodine accepted in Australia**
- **Firebrick's first patent that covers the Nasodine formulation**
- **Extends Nasodine's overall patent coverage out to 2041**
- **Patent to be filed internationally in US, EU and other key markets**

**Firebrick Pharma Limited** (ASX: FRE) (the **Company** or **Firebrick**) is pleased to announce that a patent covering the unique formulation of Nasodine<sup>®</sup> Nasal Spray ("Nasodine") has been accepted in Australia.

The patent (number 2021203846) is titled: "Virucidal Formulations Containing Povidone-iodine" and once granted, expires in June 2041. The patent will also be filed in the US, Europe and a number of other key markets.

"This is a very important development for Firebrick because it gives us our first composition patent for Nasodine," said Executive Chairman, Dr Peter Molloy.

The two pre-existing Nasodine patents, covering intranasal use of povidone-iodine (PVP-I) for the common cold and pandemic viral diseases respectively, are 'method-of-use' patents. The latest patent covers the pharmaceutical composition of the Nasodine formulation, regardless of intended use or site of application.

"If ultimately granted in the US and Europe, this patent significantly extends the patent protection around Nasodine and should make it more valuable for partnering, in my view," added Dr Molloy.

The basis for the invention claimed in the patent is that the proprietary Nasodine formulation displays enhanced virucidal activity compared with PVP-I solutions alone. This is particularly the case with human rhinovirus (HRV), which is the main cause of the common cold.

The patent discloses the results of *in vitro* studies of Nasodine against HRV-14 (rhinovirus type 14), which is one of the more difficult rhinovirus strains for PVP-I to inactivate.

The Nasodine formulation produced a 6-log reduction (99.9999%) in viable virus after 5 minutes exposure, compared with less than a 2.5 log reduction with commercial PVP-I formulations, the latter based on published data.

According to the patent, the Nasodine formulation "showed a markedly increased virucidal activity compared to other PVP-I formulations (concentrations between around 0.5% and 1.0%), at clinically-relevant exposure times of 2 and 5 minutes."

The patent also discloses that based on independent *in vitro* studies, the Nasodine formulation had enhanced antiviral activity against SARS-CoV-2 (COVID-19 virus), when compared with aqueous PVP-I solution.

A range of formulations is covered in the accepted patent claims, notably including PVP-I concentrations between 0.10% and 1.25%.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

### **About Firebrick Pharma**

Firebrick is a pharmaceutical company founded in 2012 to develop and commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The Company owns numerous granted and pending patents, including a core patent family that covers the use of intranasal povidone-iodine for the treatment and prevention of the common cold and a second patent family covering the prevention of pandemic viral diseases, including COVID-19. The Company also now has a third patent family covering the Nasodine formulation. Firebrick is completing two major clinical trials: A Phase 2 trial of Nasodine in COVID-19 and a Phase 3 trial for Nasodine, to confirm its efficacy as a treatment for the common cold and support international approvals.

#### **Media enquiries:**

Heidi Cuthbert  
+61 411 272 366  
[heidi.cuthbert@multiplier.com.au](mailto:heidi.cuthbert@multiplier.com.au)

#### **Investor enquiries:**

[Investors@firebrickpharma.com](mailto:Investors@firebrickpharma.com)